Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mark Sabag is See "Remarks" at Teva Pharmaceutical Industries. OQRO lists 8 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
See "Remarks"
Disclosures on record
8
Companies involved
1
As of the latest filing on , Mark Sabag reported holding 80,760 shares of Teva Pharmaceutical Industries (TEVA), worth about $3.59M at the last close of $45 (Nov 13, 2026). In the last 12 months, Mark Sabag sold $3.9M in 2 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 80,760 | 81K direct | $45 | $3.59M | Nov 12, 2026 |
Is this Mark Sabag’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Teva Pharmaceutical IndustriesTEVA
8 disclosures · Feb 2025 – Nov 2026 · 4 sold
Nov 12, 2026Sold~$1.97M
DetailsOfficial recordNov 12, 202645K
DetailsOfficial recordNov 12, 202645K
DetailsOfficial recordNov 5, 2026Sold~$1.93Mdisclosed Nov 6
DetailsOfficial recordNov 5, 202646Kdisclosed Nov 6
DetailsOfficial recordNov 5, 202646Kdisclosed Nov 6
DetailsOfficial recordMay 8, 2025Sold~$6.1Mdisclosed May 12
DetailsOfficial recordFeb 12, 2025Sold~$2.89Mdisclosed Feb 14
DetailsOfficial recordMark Sabag has no open-market purchase on record since 2018. Sales in each of the last 3 years.
Mark Sabag reported 0 open-market purchases and 9 sales since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $3.9M2×2 trades |
| 2025 | — | $8.98M2×2 trades |
| 2024 | — | $1.35M1×1 trade |
| 2021 | — | $1.43M1×1 trade |
| 2020 | — | $940K1×1 trade |
| 2018 | — | $99K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 12, 2026, Mark Sabag reported holding 80,760 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $3.59M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Mark Sabag reported 2 open-market sales worth $3.9M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Mark Sabag has no open-market purchase on record since 2018. Sales in each of the last 3 years.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2026.
Teva Pharmaceutical Industries (TEVA), from 2018 to 2026: 0 purchases and 9 sales.
Mark Sabag reported 0 open-market purchases and 9 sales here, 2018 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
